We are live on ! Find out more
DMK

DMK Pharmaceuticals Corporation Common Stock
DMK

Delisted

DMK was delisted on the 6th of February, 2024.

Back to rankings

51 hedge funds and large institutions have $17.8M invested in DMK Pharmaceuticals Corporation Common Stock in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 3 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

567% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 3

99% more call options, than puts

Call options by funds: $1.85M | Put options by funds: $930K

39% more capital invested

Capital invested by funds: $12.8M → $17.8M (+$5M)

4% less funds holding

Funds holding: 53 → 51 (-2)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

Holders
51
Holders Change
-2
Holders Change %
-3.77%
% of All Funds
0.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
20
Reduced
3
Closed
12
Calls
$1.85M
Puts
$930K
Net Calls
+$922K
Net Calls Change
+$1.11M

Top Buyers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$1.41M
2
GC
Greenlight Capital
New York
+$870K
3
BlackRock
BlackRock
New York
+$743K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$507K
5
State Street
State Street
Massachusetts
+$327K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$773K
2
Millennium Management
Millennium Management
New York
-$347K
3
VF
Virtu Financial
New York
-$326K
4
Citadel Advisors
Citadel Advisors
Florida
-$118K
5
Group One Trading
Group One Trading
Illinois
-$76.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
AAS
26
Avantax Advisory Services
Texas
$35K +$27.8K +457 New
TRCT
27
Tower Research Capital (TRC)
New York
$29K +$15.5K +254 +197%
BRWA
28
B. Riley Wealth Advisors
Florida
$28K +$609 +10 +3%
Citadel Advisors
29
Citadel Advisors
Florida
$25K -$118K -1,930 -86%
GSIS
30
Global Strategic Investment Solutions
Arizona
$25K – – –
Victory Capital Management
31
Victory Capital Management
Texas
$25K +$1.4K +23 +8%
FCMT
32
Founders Capital Management (Texas)
Texas
$20K +$8.71K +143 +125%
Millennium Management
33
Millennium Management
New York
$17K -$347K -5,698 -96%
OC
34
Oppenheimer & Co
New York
$13K – – –
RJA
35
Raymond James & Associates
Florida
$13K +$10.1K +166 New
HighTower Advisors
36
HighTower Advisors
Illinois
$13K +$10.6K +174 New
MOS
37
MGO One Seven
Ohio
$12K – – –
WWM
38
Wolff Wiese Magana
California
$12K – – –
Bank of America
39
Bank of America
North Carolina
$12K +$61 +1 +0.6%
Osaic Holdings
40
Osaic Holdings
Arizona
$10K +$3.47K +57 +77%
Barclays
41
Barclays
United Kingdom
$6K -$22.7K -373 -83%
FCM
42
Firestone Capital Management
Florida
$6K – – –
HCP
43
Hexagon Capital Partners
Arkansas
$6K – – –
TF
44
TimeScale Financial
Massachusetts
$6K – – –
AF
45
Allworth Financial
California
$4K – – –
HI
46
Harbour Investments
Wisconsin
$2K – – –
Bessemer Group
47
Bessemer Group
New Jersey
$1K – – –
S
48
SignatureFD
Georgia
$1K – – –
Wells Fargo
49
Wells Fargo
California
$1K +$122 +2 +17%
Renaissance Technologies
50
Renaissance Technologies
New York
– -$773K -11,752 Closed
1
2
3

DMK Hedge Fund Activity: Q2 2021 in Review

51 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q2 2021, worth a combined $17.8M — up 39% from $12.8M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of DMK and 10 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 20 added.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $1.41M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $773K sold.

  • 51 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q2 2021, down from 53 in Q1 2021.
  • Funds reported $17.8M of DMK Pharmaceuticals Corporation Common Stock stock for Q2 2021, up 39% quarter-over-quarter.
  • 10 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q2 2021 and 12 closed out, a net change of -2 holders.
  • The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q2 2021 was Balyasny Asset Management, an estimated $1.41M added.
  • The largest DMK Pharmaceuticals Corporation Common Stock seller in Q2 2021 was Renaissance Technologies, an estimated $773K sold.

Based on aggregated 13F filings for Q2 2021.